SK281964B6 - Monoklonálna protilátka schopná vyvolať apoptózu myeloidných buniek, jej fragmenty a hybridóm - Google Patents
Monoklonálna protilátka schopná vyvolať apoptózu myeloidných buniek, jej fragmenty a hybridóm Download PDFInfo
- Publication number
- SK281964B6 SK281964B6 SK255-96A SK25596A SK281964B6 SK 281964 B6 SK281964 B6 SK 281964B6 SK 25596 A SK25596 A SK 25596A SK 281964 B6 SK281964 B6 SK 281964B6
- Authority
- SK
- Slovakia
- Prior art keywords
- cells
- bmap
- antibody
- monoclonal antibody
- cell
- Prior art date
Links
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 22
- 239000012634 fragment Substances 0.000 title abstract description 4
- 210000004027 cell Anatomy 0.000 title description 124
- 230000006907 apoptotic process Effects 0.000 title description 8
- 239000000427 antigen Substances 0.000 claims abstract description 29
- 102000036639 antigens Human genes 0.000 claims abstract description 29
- 108091007433 antigens Proteins 0.000 claims abstract description 29
- 230000031957 myeloid cell apoptotic process Effects 0.000 claims abstract description 18
- 210000000066 myeloid cell Anatomy 0.000 claims description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 10
- 208000025113 myeloid leukemia Diseases 0.000 abstract 1
- 210000002798 bone marrow cell Anatomy 0.000 description 24
- 210000002536 stromal cell Anatomy 0.000 description 22
- 238000000034 method Methods 0.000 description 21
- 210000000952 spleen Anatomy 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 18
- 239000002609 medium Substances 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 15
- 238000010185 immunofluorescence analysis Methods 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 210000004989 spleen cell Anatomy 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 239000012091 fetal bovine serum Substances 0.000 description 11
- 210000003887 myelocyte Anatomy 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 description 10
- 230000003394 haemopoietic effect Effects 0.000 description 10
- 230000003053 immunization Effects 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 201000000050 myeloid neoplasm Diseases 0.000 description 10
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 208000032839 leukemia Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000009257 reactivity Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 230000007910 cell fusion Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000010322 bone marrow transplantation Methods 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000011132 hemopoiesis Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000001187 Collagen Type III Human genes 0.000 description 2
- 108010069502 Collagen Type III Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000004163 cytometry Methods 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 108010052621 fas Receptor Proteins 0.000 description 2
- 102000018823 fas Receptor Human genes 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000001167 myeloblast Anatomy 0.000 description 2
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 210000003924 normoblast Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101150064015 FAS gene Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- BGSOJVFOEQLVMH-UHFFFAOYSA-N Hydrocortisone phosphate Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)(O)C(=O)COP(O)(O)=O)C4C3CCC2=C1 BGSOJVFOEQLVMH-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
- 108010052989 Naphthol AS D Esterase Proteins 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000000006 cell growth inhibition assay Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000010293 colony formation assay Methods 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- BGSOJVFOEQLVMH-VWUMJDOOSA-N cortisol phosphate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 BGSOJVFOEQLVMH-VWUMJDOOSA-N 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000000093 cytochemical effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229950000785 hydrocortisone phosphate Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- -1 β-glucouronidase Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP05242110 | 1993-09-03 | ||
PCT/JP1994/001453 WO1995006748A1 (fr) | 1993-09-03 | 1994-09-02 | Anticorps monoclonal permettant d'induire une apoptose |
Publications (2)
Publication Number | Publication Date |
---|---|
SK25596A3 SK25596A3 (en) | 1996-10-02 |
SK281964B6 true SK281964B6 (sk) | 2001-09-11 |
Family
ID=17084452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK255-96A SK281964B6 (sk) | 1993-09-03 | 1994-09-02 | Monoklonálna protilátka schopná vyvolať apoptózu myeloidných buniek, jej fragmenty a hybridóm |
Country Status (19)
Country | Link |
---|---|
US (4) | US5840344A (sv) |
EP (1) | EP0721015B1 (sv) |
KR (1) | KR100241863B1 (sv) |
CN (1) | CN1046314C (sv) |
AT (1) | ATE280835T1 (sv) |
AU (1) | AU692466B2 (sv) |
CA (1) | CA2169950A1 (sv) |
CZ (1) | CZ294359B6 (sv) |
DE (1) | DE69434097T2 (sv) |
FI (1) | FI960567A0 (sv) |
HU (1) | HU222989B1 (sv) |
NO (1) | NO960684D0 (sv) |
PL (1) | PL181783B1 (sv) |
RU (1) | RU2202615C2 (sv) |
SK (1) | SK281964B6 (sv) |
TW (1) | TW426687B (sv) |
UA (1) | UA50708C2 (sv) |
WO (1) | WO1995006748A1 (sv) |
ZA (1) | ZA946767B (sv) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE280835T1 (de) * | 1993-09-03 | 2004-11-15 | Chugai Pharmaceutical Co Ltd | Apoptose induzierender monoklonaler antikörper |
AU2232597A (en) * | 1996-03-06 | 1997-09-22 | Chugai Seiyaku Kabushiki Kaisha | Method of screening apoptosis inducing substances |
US6828426B1 (en) | 1996-07-15 | 2004-12-07 | Chugai Seiyaku Kabushiki Kaisha | VEGF-like factor |
DE69839492D1 (de) * | 1997-09-11 | 2008-06-26 | Chugai Pharmaceutical Co Ltd | Monoklonale antikörper zur apoptosis-induzierung |
US7531643B2 (en) * | 1997-09-11 | 2009-05-12 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody inducing apoptosis |
EP1167388A4 (en) * | 1999-03-10 | 2002-05-29 | Chugai Pharmaceutical Co Ltd | APOPTOSE INDUCING SINGLE STRING FV |
US7696325B2 (en) | 1999-03-10 | 2010-04-13 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide inducing apoptosis |
US20040058393A1 (en) * | 2000-04-17 | 2004-03-25 | Naoshi Fukishima | Agonist antibodies |
DE60133479T2 (de) | 2000-10-20 | 2009-04-16 | Chugai Seiyaku K.K. | Modifizierter tpo-agonisten antikörper |
CN1308447C (zh) * | 2000-10-20 | 2007-04-04 | 中外制药株式会社 | 低分子化的激动剂抗体 |
US7195771B1 (en) | 2000-11-21 | 2007-03-27 | Kimberly-Clark Worldwide, Inc. | Water-soluble lotions for paper products |
AU2002361642A1 (en) * | 2001-11-16 | 2003-06-10 | The University Of Tennessee Research Corporation | Recombinant antibody fusion proteins and methods for detection of apoptotic cells |
ATE414105T1 (de) | 2002-10-11 | 2008-11-15 | Chugai Pharmaceutical Co Ltd | Zelltod-induzierender wirkstoff |
JP2004279086A (ja) * | 2003-03-13 | 2004-10-07 | Konica Minolta Holdings Inc | 放射線画像変換パネル及び放射線画像変換パネルの製造方法 |
EP1609803A4 (en) * | 2003-03-31 | 2006-05-24 | Chugai Pharmaceutical Co Ltd | MODIFIED ANTIBODY AGAINST CD22 AND ITS USE |
AU2004297109A1 (en) * | 2003-12-12 | 2005-06-23 | Chugai Seiyaku Kabushiki Kaisha | Cell death inducing agent |
TW200530269A (en) | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
WO2005056602A1 (ja) * | 2003-12-12 | 2005-06-23 | Chugai Seiyaku Kabushiki Kaisha | アゴニスト活性を有する改変抗体のスクリーニング方法 |
TW200530266A (en) * | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Method of reinforcing antibody activity |
US9493569B2 (en) | 2005-03-31 | 2016-11-15 | Chugai Seiyaku Kabushiki Kaisha | Structural isomers of sc(Fv)2 |
EP1927367A4 (en) * | 2005-05-18 | 2009-08-12 | Univ Tokushima | NOVEL PHARMACEUTICAL AGENT BASED ON AN ANTI-HLA ANTIBODY |
KR101360671B1 (ko) | 2005-06-10 | 2014-02-07 | 추가이 세이야쿠 가부시키가이샤 | sc(Fv)2를 함유하는 의약조성물 |
AU2006256041B2 (en) * | 2005-06-10 | 2012-03-29 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
WO2007100892A2 (en) * | 2006-02-28 | 2007-09-07 | The Board Of Trustees Of The Leland Stanford Junior University | Trojan horse immunotherapy |
AR061986A1 (es) * | 2006-07-13 | 2008-08-10 | Chugai Pharmaceutical Co Ltd | Agentes inductores de muerte celular |
CL2008000719A1 (es) * | 2007-03-12 | 2008-09-05 | Univ Tokushima Chugai Seiyaku | Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a |
KR20170108946A (ko) | 2014-12-05 | 2017-09-27 | 메모리얼 슬로안-케터링 캔서 센터 | Fc 수용체-유사 5를 표적화하는 키메라 항원 수용체 및 그의 용도 |
BR112018011336A2 (pt) | 2015-12-04 | 2018-12-04 | Memorial Sloan-Kettering Cancer Center | anticorpo anti-fcrl5 isolado ou um fragmento de ligação ao antígeno do mesmo, anticorpo scfv anti-fcrl5 isolado, anticorpo isolado ou porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico isolado, vetor de expressão, célula hospedeira, método para detectar fcrl5 em uma célula ou tecido inteiro, método para tratar câncer em um indivíduo, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo, kit para tratar câncer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE280835T1 (de) * | 1993-09-03 | 2004-11-15 | Chugai Pharmaceutical Co Ltd | Apoptose induzierender monoklonaler antikörper |
AU2232597A (en) * | 1996-03-06 | 1997-09-22 | Chugai Seiyaku Kabushiki Kaisha | Method of screening apoptosis inducing substances |
DE69839492D1 (de) * | 1997-09-11 | 2008-06-26 | Chugai Pharmaceutical Co Ltd | Monoklonale antikörper zur apoptosis-induzierung |
EP1167388A4 (en) * | 1999-03-10 | 2002-05-29 | Chugai Pharmaceutical Co Ltd | APOPTOSE INDUCING SINGLE STRING FV |
-
1994
- 1994-09-02 AT AT94925618T patent/ATE280835T1/de not_active IP Right Cessation
- 1994-09-02 ZA ZA946767A patent/ZA946767B/xx unknown
- 1994-09-02 DE DE69434097T patent/DE69434097T2/de not_active Expired - Fee Related
- 1994-09-02 WO PCT/JP1994/001453 patent/WO1995006748A1/ja active IP Right Grant
- 1994-09-02 US US08/605,059 patent/US5840344A/en not_active Expired - Lifetime
- 1994-09-02 CA CA002169950A patent/CA2169950A1/en not_active Abandoned
- 1994-09-02 CZ CZ1996617A patent/CZ294359B6/cs not_active IP Right Cessation
- 1994-09-02 SK SK255-96A patent/SK281964B6/sk unknown
- 1994-09-02 HU HU9600206A patent/HU222989B1/hu not_active IP Right Cessation
- 1994-09-02 PL PL94313260A patent/PL181783B1/pl not_active IP Right Cessation
- 1994-09-02 AU AU75466/94A patent/AU692466B2/en not_active Ceased
- 1994-09-02 KR KR1019960700821A patent/KR100241863B1/ko not_active IP Right Cessation
- 1994-09-02 CN CN94193260A patent/CN1046314C/zh not_active Expired - Fee Related
- 1994-09-02 EP EP94925618A patent/EP0721015B1/en not_active Expired - Lifetime
- 1994-09-02 RU RU96107203/13A patent/RU2202615C2/ru not_active IP Right Cessation
- 1994-09-02 UA UA96030813A patent/UA50708C2/uk unknown
- 1994-11-19 TW TW083110887A patent/TW426687B/zh not_active IP Right Cessation
-
1996
- 1996-02-07 FI FI960567A patent/FI960567A0/sv not_active Application Discontinuation
- 1996-02-21 NO NO960684A patent/NO960684D0/no not_active Application Discontinuation
-
1998
- 1998-09-17 US US09/154,498 patent/US6267959B1/en not_active Expired - Lifetime
-
2000
- 2000-12-15 US US09/736,146 patent/US6759043B2/en not_active Expired - Fee Related
-
2003
- 2003-03-03 US US10/376,628 patent/US20030147894A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2202615C2 (ru) | 2003-04-20 |
UA50708C2 (uk) | 2002-11-15 |
EP0721015A1 (en) | 1996-07-10 |
FI960567A (sv) | 1996-02-07 |
EP0721015B1 (en) | 2004-10-27 |
US6267959B1 (en) | 2001-07-31 |
KR100241863B1 (ko) | 2000-03-02 |
US20030147894A1 (en) | 2003-08-07 |
US5840344A (en) | 1998-11-24 |
SK25596A3 (en) | 1996-10-02 |
CN1046314C (zh) | 1999-11-10 |
US20010001712A1 (en) | 2001-05-24 |
ZA946767B (en) | 1995-04-03 |
PL181783B1 (pl) | 2001-09-28 |
US6759043B2 (en) | 2004-07-06 |
HU222989B1 (hu) | 2004-01-28 |
CZ294359B6 (cs) | 2004-12-15 |
CN1130405A (zh) | 1996-09-04 |
AU692466B2 (en) | 1998-06-11 |
WO1995006748A1 (fr) | 1995-03-09 |
ATE280835T1 (de) | 2004-11-15 |
CZ61796A3 (en) | 1996-06-12 |
HUT74594A (en) | 1997-01-28 |
NO960684L (no) | 1996-02-21 |
DE69434097T2 (de) | 2006-02-02 |
CA2169950A1 (en) | 1995-03-09 |
DE69434097D1 (de) | 2004-12-02 |
NO960684D0 (no) | 1996-02-21 |
FI960567A0 (sv) | 1996-02-07 |
HU9600206D0 (en) | 1996-03-28 |
TW426687B (en) | 2001-03-21 |
PL313260A1 (en) | 1996-06-24 |
AU7546694A (en) | 1995-03-22 |
EP0721015A4 (en) | 1999-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK281964B6 (sk) | Monoklonálna protilátka schopná vyvolať apoptózu myeloidných buniek, jej fragmenty a hybridóm | |
US6579692B1 (en) | Method of screening apoptosis inducing substances | |
EP2248529B1 (en) | NKG2D antibodies for use in the treatment of autoimmune or inflammatory diseases | |
KR20040106585A (ko) | 아포토시스를 유기하는 모노클로날 항체 | |
IE50420B1 (en) | Monoclonal antibody to human t cells,method for preparing it,therapeutic composition comprising it and diagnostic method using it | |
US4818689A (en) | Late differentiation antigen associated with helper T lymphocyte function | |
JP3725653B2 (ja) | アポトーシスを誘起する物質のスクリーニング方法 | |
JP3984688B2 (ja) | アポトーシスを誘起するモノクローナル抗体を有効成分とする医薬 | |
SK281965B6 (sk) | Monoklonálna protilátka inhibujúca zachytávanie krvotvorných kmeňových buniek a hybridóm | |
JP2741483B2 (ja) | アポトーシスを誘起するモノクローナル抗体 | |
JPS6363556B2 (sv) | ||
JPH08208697A (ja) | アポトーシスを誘起するモノクローナル抗体を有効成分とする医薬 | |
JPH07118299A (ja) | 間質細胞表面抗原を認識するモノクローナル抗体 |